Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 159415, 13 pages
http://dx.doi.org/10.1155/2008/159415
Review Article

Clinical Use of PPAR Ligands in Cancer

Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH 43210, USA

Received 22 March 2008; Revised 11 August 2008; Accepted 29 September 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Jennifer L. Hatton and Lisa D. Yee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The role of PPAR in adipocyte differentiation has fueled intense interest in the function of this steroid nuclear receptor for regulation of malignant cell growth and differentiation. Given the antiproliferative and differentiating effects of PPAR ligands on liposarcoma cells, investigation of PPAR expression and ligand activation in other solid tumors such as breast, colon, and prostate cancers ensued. The anticancer effects of PPAR ligands in cell culture and rodent models of a multitude of tumor types suggest broad applicability of these agents to cancer therapy. This review focuses on the clinical use of PPAR ligands, specifically the thiazolidinediones, for the treatment and prevention of cancer.